Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy Plans Local Buyouts (India)

This article was originally published in PharmAsia News

Executive Summary

Ranbaxy Laboratories plans to buy companies in India, a market that is expected to rank among the world's biggest in the next eight years. "We would certainly acquire a couple" of drugmakers, Malvinder Singh, chief executive officer of the Gurgaon-based company, said in an interview at the World Economic Forum in Dalian, China. The Indian market is expected to see "a good amount of consolidation" in the next five years, he said. India's patent laws were tightened in January 2005 to recognize product patents and stop the copying of medicines patented after 1995 by using a different manufacturing process. That may hurt drugmakers which aren't engaging in new drug research or those that don't have a strong generics business overseas, making them acquisition targets. "Small and mid-sized companies will find it tougher to survive in this environment," said Sarabjit Kour Nangra, an analyst with Angel Broking in Mumbai. "New product introductions are going to come down, which will cap their growth." (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts